|Day Low/High||53.90 / 54.37|
|52 Wk Low/High||53.76 / 77.12|
The drug maker long has been a growth stock, but a big drop in market cap has brought it down to a reasonable price with a decent dividend to boot.
Cramer says Thor Industries does everything right and Bristol-Myers should be held for the long term.
Cramer's got a new acronym for growth -- FAAA.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
With the Fed decision behind it, the market focuses on earnings and oil. In the portfolio, we added to three positions and exited from one.
This drug stock has stumbled on a failed clinical trial, but here's why the stock is a bargain right now.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York.
A quick-turning reversal pattern is all that is needed to set things in motion.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo to include the...
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher and Suono Bio are the...
The market gets pushed and pulled by the Fed, oil and loads of economic reports. Meanwhile, the portfolio includes a new name.
Cramer says Bristol-Myers is the value stock to own and Foot Locker is doing as well as he predicted.
Demand is quite healthy and markets are not going into the abyss, Cramer says.
Bristol-Myers' (BMY) stock price target was cut to $57 at Jefferies on Monday.
Oil, Fed chatter throw a wrench in the end of the week. In the portfolio, we add to 2 names and drop another.
2 ways to play it -- aggressive or conservative -- as the bullish crossover returns.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016.
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Wednesday, September 14, 2016, in London.
Today, the first of six teams of Bristol-Myers Squibb Company (NYSE:BMY) oncology employees set out from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride , a 21-day cycling ride...
The major indexes may have been flat during the month of August, but there was a lot of buying under the surface, especially in popular stocks like Facebook and Ford.
The European Commission approved Bristol-Myers Squibb's (BMY) Orencia rheumatoid arthritis drug on Tuesday for use in patients that have not yet been treated with methotrexate.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in combination with...
The market stayed in a narrow range as oil, the Fed and jobs took the headlines. We added to 2 portfolio positions.